Marriott Q1 2026 Beats on EPS, RevPAR Growth, but Expensive Valuation Keeps Us on Sidelines

What happened

Marriott reported Q1 2026 RevPAR growth of 4.2% worldwide (4.0% U.S./Canada, 4.6% international) and adjusted EPS of $2.72, beating the implied annualized pace from guidance. Net rooms grew 4.5% year-over-year, with a record pipeline of nearly 618,000 rooms, and the company returned $1.2 billion to shareholders year-to-date. However, the DeepValue Master Report highlights a stretched valuation at 36.2x P/E and 24.4x EV/EBITDA, with net debt/EBITDA of 3.73x, leaving no margin of safety. The earnings quality is clouded by $1.409 billion in deferred co-brand revenue and a $102 million estimate revision in 2025, making the reported co-brand fee growth trajectory uncertain. While Q1 results support the base case of $360, the bear case risk of co-brand recognition deferral and elevated deletions remains relevant, reinforcing the 'Wait' rating.

Implication

Marriott's Q1 2026 results validate near-term execution on RevPAR and unit growth, but the investment thesis hinges on two pivotal factors: sustained 4.5-5.0% net rooms growth and a ~35% co-brand fee increase. While RevPAR exceeded guidance, the co-brand fee trajectory remains opaque due to accounting estimate sensitivity and the $1.4 billion deferred revenue overhang. The stock's expensive valuation (36x P/E) means any shortfall could lead to significant multiple compression. Aggressive share repurchases buy time but increase leverage. Longer-term, the bull case depends on U.S. co-brand renegotiation and international expansion, but Q1 provides no clarity. Therefore, investors should remain on the sidelines until the next quarter confirms fee acceleration and conversion pipeline stability.

Thesis delta

Q1 2026 results align with the base case from the DeepValue report, supporting the 'Wait' rating rather than shifting to 'Buy'. The key thesis breakers—co-brand fee growth tracking below ~35% and net rooms growth falling below 4.5%—have not been triggered, but also not yet confirmed. The slight outperformance in RevPAR does not change the crowded bullish narrative or the lack of margin of safety, so the call remains to wait for more evidence before entry near the attractive entry of $310.